List view / Grid view

News

NICE says ‘no’ to Opdivo for non-squamous NSCLC

12 May 2016 | By Victoria White, Digital Content Producer

In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...

Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022

11 May 2016 | By Victoria White, Digital Content Producer

Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.